An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia.
Aplastic anemia
Cyclophosphamide
Fludarabine
Survival
Transplantation
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
16
08
2020
revised:
26
01
2021
accepted:
31
01
2021
entrez:
9
5
2021
pubmed:
10
5
2021
medline:
3
7
2021
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (HSCT) using fludarabine (Flu)-based conditioning regimens are being increasingly being used in patients with aplastic anemia (AA). We describe an antithymocyte globulin (ATG)-free conditioning regimen consisting of Flu and cyclophosphamide (Cy) in patients undergoing matched related donor (MRD) HSCT for AA. Between 2004 and 2019, 212 patients underwent MRD HSCT using Flu (30 mg/m
Identifiants
pubmed: 33965181
pii: S2666-6367(21)00667-9
doi: 10.1016/j.jtct.2021.01.029
pii:
doi:
Substances chimiques
Antilymphocyte Serum
0
Cyclophosphamide
8N3DW7272P
Vidarabine
FA2DM6879K
fludarabine
P2K93U8740
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
409.e1-409.e6Informations de copyright
Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.